BIRMINGHAM WOMEN'S NHS FOUNDATION TRUST

INCOME & EXPENDITURE

REPORTING PERIOD : - February 09 (Period 11)

Form F1	This Month			Year To Date			Full Year Forecast		
	Plan	Actual	Fav/(Adv)	Plan	Actual	Fav/(Adv)	Plan	Actual	Fav/(Adv)
Income (+)	£ 000's	£ 000's	£ 000's	£ 000's	£ 000's	£ 000's	£ 000's	£ 000's	£ 000's
Healthcare Income	5,032	4,984	(48)	55,125	55,952	827	60,157	61,258	1,101
Private Patient Income	100	87	(13)	1,101	932	(170)	1,201	1,016	(185)
Other Income	1,542	1,710	168	14,683	15,052	369	15,708	16,140	433
Total Income	6,675	6,782	107	70,909	71,936	1,027	77,066	78,414	1,349
Operating Costs (-)									
Pay Costs	(4,310)	(4,273)	36	(47,113)	(46,770)	342	(51,928)	(51,590)	338
Non Pay Costs	(1,899)	(1,986)	(87)	(18,668)	(19,550)	(883)	(19,543)	(20,454)	(911)
Total Operating Costs	(6,209)	(6,260)	(51)	(65,780)	(66,321)	(540)	(71,471)	(72,044)	(573)
EBITDA	466	522	56	5,129	5,615	486	5,595	6,370	776
EBITDA % Margin	7.0%	7.7%	0.7%	7.2%	7.8%	0.6%	7.3%	8.1%	0.9%
Depreciation (-)	(303)	(265)	39	(3,338)	(2,923)	414	(3,641)	(3,326)	315
Interest (+/-)	31	7	(24)	346	392	46	377	397	20
Surplus / Deficit before dividend	194	264	71	2,137	3,084	947	2,331	3,442	1,111
Dividend (-)	(147)	(147)	0	(1,612)	(1,612)	0	(1,759)	(1,759)	0
Surplus / (Deficit) cfd	47	118	71	525	1,472	947	572	1,683	1,111







Balance Sheet

	Jan 09	Feb 09
Balance sheet		
FIXED ASSETS		
Tangible + Intangible Assets	46,415	46,361
Total Fixed Assets	**46,415**	**46,361**
CURRENT ASSETS		
Stocks & Work in Progress	385	385
NHS Debtors	1,501	1,420
Non NHS Trade Debtors	631	399
Accrued Income & Prepayments	1,369	1,784
Cash at bank and in hand	10,886	11,863
Total Current Assets	**14,772**	**15,851**
CURRENT LIABILITIES (amounts due in less than one year)		
Trade Creditors	1,516	2,078
Other Creditors	1,138	1,898
PDC dividend creditor	586	733
Capital Creditors	633	528
NHS Creditors	2,352	2,691
Accruals & deferred income	5,726	4,936
Total Current Liabilities	**11,952**	**12,864**
NET CURRENT ASSETS (LIABILITIES)	**2,820**	**2,987**
Long term Debtors		
TOTAL ASSETS LESS CURRENT LIABILITIES	**49,235**	**49,348**
Creditors: Amounts falling due after more than one year		
Provisions for liabilities and charges	58	58
TOTAL ASSETS EMPLOYED	**49,177**	**49,290**
TAXPAYERS' EQUITY		
Public dividend capital	40,159	40,159
Income and expenditure reserve	4,917	5,035
Revaluation reserve	3,190	3,190
Donated asset reserve	911	906
Other Reserves (Government grant reserve etc)	-	-
TOTAL TAXPAYERS EQUITY	**49,177**	**49,290**
TOTAL FUNDS EMPLOYED	**49,177**	**49,290**

Capex program

	Plan	Actual
Capital Equipment Replacement	500	1,120
Modular Theatres	0	51
Neonatal Unit Upgrade / Decant	700	457
PACS	0	202
Pan Birmingham Decontamination	0	113
CHP Installation	1,300	1,475
Replacement PCs	200	57
Backlog Maintenance	500	468
Other	900	40
TOTAL CAPITAL PROGRAMME	**4,100**	**3,982**

BIRMINGHAM WOMEN'S NHS FOUNDATION TRUST
CASHFLOW STATEMENT
REPORTING PERIOD : - February 09 (Period 11)

Form F7	Year To Date												
	APR ACT £000's	MAY ACT £000's	JUN ACT £000's	JUL ACT £000's	AUG ACT £000's	SEP ACT £000's	OCT ACT £000's	NOV ACT £000's	DEC ACT £000's	JAN ACT £000's	FEB ACT £000's	MAR ACT £000's	TOTAL ACT £000's
INFLOWS													
PCT/SHA	4,301	5,597	4,613	4,815	5,042	5,139	5,718	5,034	5,321	4,606	4,919		55,105
VAT	25	50	50	48	15	47	42	39	43	58	56		473
OTHER	2,384	1,903	2,174	1,665	1,075	1,449	634	1,548	1,276	5,007	1,891		21,006
INT RECEIVABLE	46	38	47	50	52	39	62	32	30	14	11		421
NEW PDC	0	0	0	0	0	0	0	0	0	0	0		0
Trust Inflows	6,756	7,588	6,884	6,578	6,184	6,674	6,456	6,653	6,670	9,685	6,877	0	77,005
HA AGENCY													
TOTAL INFLOWS	6,756	7,588	6,884	6,578	6,184	6,674	6,456	6,653	6,670	9,685	6,877	0	77,005
OUTFLOWS													
PAYROLL	2,350	2,358	2,363	2,465	2,530	2,506	2,518	2,450	2,516	2,519	2,496		27,071
PURCHASES/NON-PAY	2,294	2,226	2,051	2,355	2,265	2,596	2,243	3,083	2,094	2,792	1,336		25,335
TAX/NI/SUPERANN	27	1,647	1,653	1,628	1,708	1,764	1,619	1,682	1,688	1,703	1,706		16,825
OTHER													0
CAPITAL	433	83	100	297	221	210	467	824	54	954	363		4,006
INTEREST PAYABLE													0
PDC REPAYABLE													0
DIVIDENDS													0
Trust Outflows	5,104	6,314	6,167	6,745	6,724	7,076	6,847	8,039	6,352	7,968	5,901	0	73,237
AGENCY													
	5,104	6,314	6,167	6,745	6,724	7,076	6,847	8,039	6,352	7,968	5,901	0	73,237
BALANCE B/FWD	8,092	9,744	11,018	11,735	11,568	11,028	10,626	10,235	8,849	9,167	10,884	11,860	11,860
Cash in Hand													
CASHFLOW + / -	1,652	1,274	717	(167)	(540)	(402)	(391)	(1,386)	318	1,717	976	0	
BALANCE C/FWD	9,744	11,018	11,735	11,568	11,028	10,626	10,235	8,849	9,167	10,884	11,860	11,860	11,860
Actual Balances													
PGO A/C	9,744	10,883	11,732	11,503	4,785	4,029	9,348	7,764	7,886	9,344	9,969		
Main A/C	0	138	0	65	228	599	889	1,085	1,290	1,540	1,891		
Investment Account	0	0	0	0	6,000	6,000	0	0	0	0	0		
Cash in Hand													
Report	9,744	11,021	11,732	11,568	11,013	10,628	10,237	8,849	9,176	10,884	11,860	0	0
Cash in Transit	0	3	(3)	0	(15)	2	2	0	9	0	0	(11,860)	

Risk Rating

	Year to Date April to February 09 (Period 11)		Year-end Forecast March 09		Annual Plan EOY Monitor Submission	
Financial Risk Rating						
Metric						
EBITDA margin	7.8%	3	8.1%	3	7.6%	3
EBITDA, % achieved	109.5%	5	113.9%	5	110.9%	5
ROA	6.9%	5	7.1%	5	4.8%	3
I&E surplus margin	2.0%	4	2.1%	4	0.8%	2
Liquid ratio	73.6	5	45.2	5	72.9	5
Weighted Average		4.3		4.3		3.5
Financial Criteria						
Underlying Performance		3		3		3
Achievment of Plan		5		5		5
Financial Efficiency		5		5		3
Liquidity		5		5		5
Overriding rules						
One financial criterion scored at '1'	NO		NO		NO	
One financial criterion scored at '2'	NO		NO		NO	
Two financial criteria scored at '2'	NO		NO		NO	
Two financial criteria at '1'	NO		NO		NO	
PBC breached	1.0		1.0		NO	
Less than 1 year as an Foundation Trust	YES	4	NO		YES	4
Plan submitted on time					YES	
Plans submitted complete and correct					YES	
PDC dividend paid in full					YES	
Year 2 OR Year 3 deficit					NO	
Year 2 AND Year 3 deficit					NO	
Lowest ranked metric a '1'?					NO	
Overriding rules rating		**4**		**0**		**4**
Overall Rating		**4**		**4**		**4**
Risk Rating to calculate maximum debt to assets ratio		**4**		**4**		**4**
Maximum Debt/ Assets Ratio		25%		25%		25%

Current Risk Ratings:

	Weight	5	4	3	2	1
EBITDA margin	25%	11%	9%	5%	1%	<1%
EBITDA, % achieved	10%	100%	85%	70%	50%	<50%
ROA	20.0%	6%	5%	3%	-2%	< -2%
I&E surplus margin	20.0%	3%	2%	1%	-2%	< -2%
Liquid ratio	25.0%	35	25	15	10	<10
	100%					

Rating Table

2
3
2
1
2
4
3
3
2
3
2
2

5	4	3	2	1
40%	25%	15%	10%	0%

Non Financial Risk Ratings

Governance	Green
Mandatory Services	Green

Liquidity ratio limit

Days in year	365	365	
Financial year start	01 Apr 08	01 Apr 08	
Current period end	28 Feb 09	31 Mar 09	
No of days year to date	334	365	
Original liquid ratio	74	45	73
Working Capital Facility	5,500	5,500	5,500
Committed financing facility as no. days costs	28	28	29
Maximum allowance	30	30	30
Revised liquid ratio with maximum committed facility	74	45	73

	Mar - 08	Apr - 08	May - 08	Jun - 08	Jul - 08	Aug - 08	Sep - 08	Oct - 08	Nov - 08	Dec - 08	Jan - 09	Feb - 09	Mar - 09	Apr - 09	May - 09	Jun - 09	Jul - 09	Aug - 09	Sep - 09	Oct - 09	Nov - 09	Dec - 09	Jan - 10	Feb - 10	Mar - 10
Annual Planning submission	9.4	9.7	9.0	8.8	9.1	9.5	8.9	9.1	9.2	9.4	9.2	9.0	7.9	8.1	8.3	8.6	9.1	9.6	9.2	9.6	10.0	10.4	9.6	9.9	9.3
Actual Cash Balance	8.1	9.7	11.0	11.7	11.6	11.0	10.6	10.2	8.8	9.2	10.9	11.9													
Working Capital Facility	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5	-5.5



	Mar - 08	Apr - 08	May - 08	Jun - 08	Jul - 08	Aug - 08	Sep - 08	Oct - 08	Nov - 08	Dec - 08	Jan - 09	Feb - 09	Mar - 09	Apr - 09	May - 09	Jun - 09	Jul - 09	Aug - 09	Sep - 09	Oct - 09	Nov - 09	Dec - 09	Jan - 10	Feb - 10	Mar - 10
Annual Planning Submission	1.165	0.049	0.090	0.129	0.172	0.216	0.260	0.316	0.373	0.430	0.481	0.532	0.585	0.075	0.150	0.226	0.304	0.383	0.462	0.542	0.623	0.706	0.787	0.868	0.951
Actual I&E position		0.081	0.090	0.498	0.471	0.538	0.597	0.692	0.739	1.289	1.354	1.472													



Maternity Services I&E Statement for the Period Ended 28 February 2009

	28 February 2009			Forecast At 31 March 2009		
	Plan £000	Actual £000	Variance £000	Plan £000	Actual £000	Variance £000
Income						
Maternity Contract Income	17,307	17,917	611	18,906	19,573	667
Community Midwifery	2,383	2,383	0	2,600	2,600	0
Fetal Medicine WMSSA	1,443	1,443	0	1,576	1,576	0
Fetal Medicine Outside Region	147	161	14	160	176	16
Ward Attenders	32	32	0	35	35	0
MFF and Transitional Relief	2,206	2,249	43	2,406	2,569	163
Private Patient/Overseas Patients/Amenity Beds Income	11	12	1	12	12	0
Training, Education, Research & CEAs (From DOH)	1,881	2,019	138	2,052	2,265	213
Other Income	358	347	(10)	390	372	(19)
Sub Total Income	**25,766**	**26,563**	**797**	**28,137**	**29,177**	**1,040**
Direct/Indirect Costs						
Pay	(12,641)	(12,480)	161	(13,841)	(13,703)	137
Non Pay	(1,326)	(1,394)	(68)	(1,446)	(1,534)	(88)
CNST Contribution	(2,329)	(2,329)	0	(2,541)	(2,541)	0
Sub Total Expenditure	**(16,296)**	**(16,203)**	**93**	**(17,827)**	**(17,778)**	**49**
Surplus/(Deficit) Before Apportioned Costs	**9,470**	**10,360**	**889**	**10,310**	**11,399**	**1,089**
Apportioned/Support Costs						
Clinical Support	(3,456)	(3,508)	(52)	(3,771)	(3,833)	(63)
Non Clinical Support	(4,071)	(4,203)	(131)	(4,435)	(4,545)	(110)
Earnings Before Interest, Tax, Depreciation and Amortisation	**1,942**	**2,649**	**706**	**2,104**	**3,021**	**916**
Depreciation	(1,270)	(1,112)	158	(1,385)	(1,265)	120
Interest Received	155	176	21	169	178	9
Surplus/(Deficit) Before Dividend	**827**	**1,712**	**885**	**888**	**1,933**	**1,045**
Dividend	(722)	(722)	0	(788)	(788)	0
Surplus/(Deficit)	**105**	**990**	**885**	**100**	**1,145**	**1,045**

Gynaecology & ACU I&E Statement for the Period Ended 28 February 2009

	28 February 2009			Forecast At 31 March 2009		
	Plan £000	Actual £000	Variance £000	Plan £000	Actual £000	Variance £000
Income						
Gynaecology Contract Income	10,064	9,875	(189)	10,992	10,785	(207)
EPAU	83	83	0	90	90	0
IVF	773	773	0	843	843	0
MFF and Transitional Relief	1,282	1,307	25	1,399	1,493	94
Private Patient/Overseas Patients/Amenity Beds Income	923	830	(92)	1,006	909	(98)
Training, Education, Research & CEAs (From DOH)	446	479	33	487	537	51
Other Income	268	116	(152)	296	196	(100)
Sub Total Income	**13,839**	**13,463**	**(376)**	**15,114**	**14,855**	**(259)**
Direct / Indirect Costs						
Pay	(6,590)	(6,579)	12	(7,187)	(7,189)	(2)
Non Pay	(963)	(1,097)	(133)	(1,052)	(1,197)	(145)
CNST Contribution	(5)	(5)	0	(6)	(6)	0
Sub Total Expenditure	**(7,559)**	**(7,680)**	**(121)**	**(8,244)**	**(8,391)**	**(147)**
Surplus / (Deficit) Before Apportioned Costs	**6,280**	**5,783**	**(497)**	**6,869**	**6,463**	**(406)**
Apportioned / Support Costs						
Clinical Support	(3,218)	(3,266)	(48)	(3,511)	(3,569)	(58)
Non Clinical Support	(1,917)	(1,979)	(62)	(2,089)	(2,141)	(52)
Earnings Before Interest, Tax, Depreciation and Amortisation	**1,144**	**537**	**(607)**	**1,270**	**754**	**(516)**
Depreciation	(820)	(718)	102	(895)	(817)	77
Interest Received	62	71	8	68	72	4
Surplus / (Deficit) Before Dividend	**386**	**(110)**	**(497)**	**443**	**8**	**(435)**
Dividend	(291)	(291)	0	(317)	(317)	0
Surplus / (Deficit)	**96**	**(401)**	**(497)**	**126**	**(309)**	**(435)**

Genetics I&E Statement for the Period Ended 28 February 2009

	28 February 2009			Forecast At 31 March 2009		
	Plan £000	Actual £000	Variance £000	Plan £000	Actual £000	Variance £000
Income						
Clinical Genetics WMSSA	3,018	3,018	0	3,296	3,296	0
Clinical Genetics Outside Region	82	129	47	90	141	51
Cytogenetics WMSSA	5,645	5,645	0	6,165	6,165	0
Cytogenetics Outside Region	246	391	145	269	427	158
Private Patient/Overseas Patients/Amenity Beds Income	113	33	(80)	124	35	(89)
Training, Education, Research & CEAs (From DOH)	680	729	50	741	818	77
Other Income	2,783	3,290	507	3,638	4,057	419
Sub Total Income	**12,568**	**13,236**	**668**	**14,323**	**14,940**	**617**
Direct/Indirect Costs						
Pay	(8,819)	(8,820)	(1)	(10,218)	(10,169)	49
Non Pay	(1,354)	(1,903)	(548)	(1,516)	(2,109)	(593)
CNST Contribution	(18)	(18)	0	(19)	(19)	0
Sub Total Expenditure	**(10,191)**	**(10,741)**	**(550)**	**(11,753)**	**(12,297)**	**(544)**
Surplus/(Deficit) Before Apportioned Costs	**2,377**	**2,495**	**119**	**2,570**	**2,642**	**73**
Apportioned/Support Costs						
Clinical Support	(367)	(372)	(5)	(400)	(407)	(7)
Non Clinical Support	(915)	(945)	(30)	(997)	(1,022)	(25)
Earnings Before Interest, Tax, Depreciation and Amortisation	**1,095**	**1,178**	**84**	**1,173**	**1,214**	**41**
Depreciation	(686)	(601)	85	(749)	(684)	65
Interest Received	65	74	9	71	75	4
Surplus/(Deficit) Before Dividend	**474**	**651**	**178**	**495**	**605**	**110**
Dividend	(303)	(303)	0	(331)	(331)	0
Surplus/(Deficit)	**171**	**348**	**178**	**164**	**274**	**110**

Neonatal I&E Statement for the Period Ended 28 February 2009

	28 February 2009			Forecast At 31 March 2009		
	Plan £000	Actual £000	Variance £000	Plan £000	Actual £000	Variance £000
Income						
Baby Clinic	216	228	12	236	249	13
Neonatal WMSSA	7,337	7,415	78	8,016	8,109	93
Neonatal Outside Region	156	342	186	170	374	204
Training, Education, Research & CEAs (From DOH)	647	694	47	706	779	73
Other Income	247	327	80	267	335	68
Sub Total Income	**8,603**	**9,006**	**404**	**9,395**	**9,846**	**451**
Direct / Indirect Costs						
Pay	(5,680)	(5,584)	96	(6,197)	(6,108)	89
Non Pay	(486)	(617)	(131)	(528)	(679)	(151)
CNST Contribution	(98)	(98)	0	(107)	(107)	0
Sub Total Expenditure	**(6,264)**	**(6,299)**	**(34)**	**(6,832)**	**(6,894)**	**(62)**
Surplus / (Deficit) Before Apportioned Costs	**2,338**	**2,708**	**369**	**2,563**	**2,952**	**389**
Apportioned / Support Costs						
Clinical Support	(218)	(221)	(3)	(238)	(242)	(4)
Non Clinical Support	(1,357)	(1,400)	(44)	(1,478)	(1,514)	(37)
Earnings Before Interest, Tax, Depreciation and Amortisation	**764**	**1,086**	**322**	**847**	**1,196**	**348**
Depreciation	(422)	(369)	52	(460)	(420)	40
Interest Received	51	58	7	56	59	3
Surplus / (Deficit) Before Dividend	**393**	**775**	**382**	**443**	**834**	**391**
Dividend	(240)	(240)	0	(261)	(261)	0
Surplus / (Deficit)	**154**	**535**	**382**	**182**	**573**	**391**

Clinical Support I&E Statement for the Period Ended 28 February 2009

	28 February 2009			Forecast At 31 March 2009		
	Plan £000	Actual £000	Variance £000	Plan £000	Actual £000	Variance £000
Income						
AFP	307	304	(3)	335	332	(3)
Cytology	648	648	0	707	707	0
Direct Access	188	188	1	205	206	1
Physiotherapy	129	129	0	140	140	0
Post Mortems WMSSA	723	723	0	789	789	0
Post Mortems Outside Region	7	53	46	7	57	50
Thalassaemia Screening	16	16	0	18	18	0
Private Patient/Overseas Patients/Amenity Beds Income	54	56	2	59	60	1
Training, Education, Research & CEAs (From DOH)	109	117	8	119	131	12
Other Income	1,503	1,560	57	1,640	1,682	42
Sub Total Income	**3,684**	**3,794**	**110**	**4,020**	**4,123**	**103**
Direct / Indirect Costs						
Pay	(5,928)	(6,078)	(150)	(6,466)	(6,646)	(180)
Non Pay	(4,603)	(4,683)	(81)	(5,023)	(5,085)	(62)
CNST Contribution	(6)	(6)	0	(7)	(7)	0
Sub Total Expenditure	**(10,537)**	**(10,767)**	**(231)**	**(11,496)**	**(11,738)**	**(242)**
Surplus / (Deficit) Before Apportioned Costs	**(6,853)**	**(6,973)**	**(120)**	**(7,476)**	**(7,615)**	**(140)**
Apportioned / Support Costs						
Clinical Support	7,259	7,368	109	7,919	8,051	132
Non Clinical Support	(223)	(230)	(7)	(243)	(249)	(6)
Earnings Before Interest, Tax, Depreciation and Amortisation	**183**	**164**	**(19)**	**200**	**186**	**(14)**
Depreciation	(140)	(122)	17	(152)	(139)	13
Interest Received	12	14	2	13	14	1
Surplus / (Deficit) Before Dividend	**56**	**56**	**(0)**	**61**	**61**	**(0)**
Dividend	(57)	(57)	0	(62)	(62)	0
Surplus / (Deficit)	**(1)**	**(1)**	**(0)**	**(1)**	**(1)**	**(0)**

Corporate & Facilities I&E Statement for the Period Ended 28 February 2009

	28 February 2009			Forecast At 31 March 2009		
	Plan £000	Actual £000	Variance £000	Plan £000	Actual £000	Variance £000
Income						
Other (Balancing Figure)	561	500	(61)	567	507	(60)
Emergency Threshhold	127	0	(127)	138	0	(138)
Other Income	5,762	5,373	(388)	5,371	4,968	(404)
Sub Total Income	**6,450**	**5,873**	**(576)**	**6,077**	**5,474**	**(603)**
Direct / Indirect Costs						
Pay	(7,455)	(7,231)	224	(8,020)	(7,775)	245
Non Pay	(9,935)	(9,857)	78	(9,979)	(9,851)	128
CNST Contribution	2,457	2,457	(0)	2,680	2,680	(0)
Sub Total Expenditure	**(14,934)**	**(14,631)**	**303**	**(15,319)**	**(14,946)**	**373**
Surplus / (Deficit) Before Apportioned Costs	**(8,484)**	**(8,758)**	**(274)**	**(9,242)**	**(9,471)**	**(230)**
Apportioned / Support Costs						
Clinical Support	0	0	0	0	0	0
Non Clinical Support	8,484	8,758	274	9,242	9,471	230
Earnings Before Interest, Tax, Depreciation and Amortisation	**0**	**0**	**0**	**0**	**0**	**0**
Depreciation	0	0	0	0	0	0
Interest Received	0	0	0	0	0	0
Surplus / (Deficit) Before Dividend	**0**	**0**	**0**	**0**	**0**	**0**
Dividend	0	0	0	0	0	0
Surplus / (Deficit)	**0**	**0**	**0**	**0**	**0**	**0**